

10/566292

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

ALMIRANTE, et al.

Application No.: New Application

Filed: January 27, 2006

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: 026220-00073

For: ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

January 27, 2006

Sir:


Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached Form PTO-SB08 A&B. Unless otherwise indicated herein, one copy of each item(s) is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date or the date of filing a CPA, OR (b) before the mailing date of a first Office Action on the merits in the present application, or (c) accompanies a Request for Continued Examination. No certification or fee is required.
- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

10/566292

- ☐ c. A check in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check in the amount of \$130.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

Respectfully submitted,



Richard J. Berman
Registration No. 39,107

Customer No. 004372
Arent Fox PLLC
1050 Connecticut Avenue, N.W., Suite 400
Washington, D.C. 20036-5339
Tel: (202) 857-6000
Fax: (202) 638-4810

RJB:msp

Enclosures: Form PTO-SB08A&B; Search Report; References (18)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
Form PTO/SB/08a

Application Number	New Application
Filing Date	January 27, 2006
First Named Inventor	ALMIRANTE, et al.
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	026220-00073

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Form PTO/SB/08b				Application Number	New Application
				Filing Date	January 27, 2006
				First Named Inventor	ALMIRANTE, et al.
				Art Unit	UNKNOWN
				Examiner Name	UNKNOWN
Sheet	2	of	2	Attorney Docket Number	026220-00073

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BRESCHI, et al.; "NO-Sartans: A new Class of Pharmacodynamic Hybrids as Cardiovascular Drugs"; April 30, 2004; Journal of Medicinal Chemistry	
		Sean C. SWEETMAN; "Martindale-The Complete Drug Reference"; Thirty-third Edition	
		Paolo GRESELE; "Role of Proaggregatory and Antiaggregatory Prostaglandins in Hemostasis"; November 1987; The American Society for Clinical Investigation, Inc.; Volume 80, Pages 1435-1445	
		WANSTALL, et al.; "Vascular Smooth Muscle Relaxation Mediated by Nitric Oxide Donors: A Comparison with Acetylcholine, Nitric Oxide and Nitroxyl Ion"; 2001; British Journal of Pharmacology; Pages 463-472	
		HEDNER, et al.; "A Comparison of the Angiotensin II Antagonists Valsartan and Losartan in the Treatment of Essential Hypertension"; 1999; American Journal of Hypertension, Ltd.; Vol. 12 No. 4 Part 3; Pgs. 414-417	
		M.McINTYRE, et al.; "Losartan, An Orally Active Angiotensin (AT1) Receptor Antagonist A Review of Its Efficacy and Safety in Essential Hypertension"; 1997; Vol. 74, No. 2, Pages 181-194	
		Thomas HEDNER; "The Clinical Profile of the Angiotensin II Receptor Blocker Eprosartan"; 2002; Journal of Hypertension Volume 20	
		GRESELE, et al.; "Olmesartan Medoxomil CS-866 Benevas"; 2000; Prous Science; Pages 1217-1218	
		MERLOS, et al.; TELMISARTAN; 1997; Drugs of the Future; Pages 1112-1116	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.